JointMedica

About JointMedica

JointMedica is a UK-based orthopaedic design and manufacturing company founded in 2000 by Professor Derek McMinn and Mr. Ronan Treacy. The founders were the principal designing surgeons of the clinically successful Birmingham Hip Resurfacing (BHR) device. The company leverages this deep expertise to create advanced orthopaedic implants, specifically focusing on hip arthroplasty solutions for younger, more active patients.

The company's flagship product is the Polymotion® Hip Resurfacing (PHR®) System. This implant is designed to offer the benefits of traditional hip resurfacing, such as bone conservation and the restoration of natural biomechanics, while mitigating the risks associated with metal-on-metal implants. The Polymotion® system features a metal femoral cap but utilizes an advanced, Vitamin E-infused, all-polyethylene acetabular cup with a titanium coating, creating a metal-on-polyethylene articulation. This design aims to reduce wear debris, a concern that previously limited the use of hip resurfacing, especially in female patients. The product received a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA), and as of mid-2025, is undergoing an Investigational Device Exemption (IDE) study to evaluate its safety and effectiveness.

JointMedica operates as a private company headquartered in Worcestershire, UK. It functions as an orthopaedic 'Think Tank,' collaborating closely with surgeons to develop its products. The company's business model involves designing, manufacturing, and bringing these high-classification medical devices to market. In January 2022, Exactech, a global medical device company, acquired a minority interest in JointMedica. This strategic partnership provides JointMedica with global distribution and commercialization resources, with Exactech holding exclusive global distribution rights for the Polymotion® system, which will be marketed on a country-by-country basis following regulatory approvals.